Cargando…

Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

OBJECTIVES: We describe the development of Your Multiple Sclerosis Questionnaire and present the real-world usability testing results of Your Multiple Sclerosis Questionnaire. METHODS: The Your Multiple Sclerosis Questionnaire tool was developed in four stages to collect feedback from people living...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giovannoni, Gavin, Alvarez, Enrique, Tutton, Ellen, Hoffmann, Olaf, Xu, Yan, Vermersch, Patrick, Oreja-Guevara, Celia, Trojano, Maria, Gold, Ralf, Robles-Cedeño, René, Khwaja, Mudeer, Stadler, Bianca, Vandercappellen, Jo, Ziemssen, Tjalf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185975/ https://www.ncbi.nlm.nih.gov/pubmed/37205165 http://dx.doi.org/10.1177/20552076231173531

Ejemplares similares

Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Improving patient–physician dialog: commentary on the results of the MS Choices survey
por: Lugaresi, Alessandra, et al.
Publicado: (2012)

Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool
por: Hobart, Jeremy, et al.
Publicado: (2022)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021)

Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
por: Oreja-Guevara, Celia, et al.
Publicado: (2019)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany
por: Balakrishnan, Preetha, et al.
Publicado: (2022)

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

The COVID-19 pandemic and the use of MS disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
por: Barclay, Krista, et al.
Publicado: (2019)

Future MS care: a consensus statement of the MS in the 21st Century Steering Group
por: Rieckmann, Peter, et al.
Publicado: (2012)

Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
por: Akgün, Katja, et al.
Publicado: (2019)

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
por: Giovannoni, Gavin
Publicado: (2022)

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
por: Comi, Giancarlo, et al.
Publicado: (2019)

Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
por: Van Wijmeersch, Bart, et al.
Publicado: (2022)

Cognition and its relation to brain health in patients with MS: Response to letter
por: Hobart, Jeremy, et al.
Publicado: (2020)

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
por: Ness, Nils-Henning, et al.
Publicado: (2020)

Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS
por: Moser, Tobias, et al.
Publicado: (2020)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ed5doj37jn3oq2psiasnfu7dh